Recollections on thrombin generation
Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants
Double-blindness protects scientific validity
Open-label trials and drug registration: a European regulator's view
Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells
The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions
Venous thromboembolism and subsequent short-term risk of an occult cancer
Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry
Coagulation factors, activation markers and risk of coronary heart disease: the Northwick Park Heart Studies
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII)
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children
Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants
Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk
Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review
Tissue-specific hemostasis: role of tissue factor
Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice
Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies
A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry
Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura
A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor
Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities
Immunologic and structural analysis of eight novel domain-deletion β3 integrin peptides designed for detection of HPA-1 antibodies
Three novel β3 domain-deletion peptides for the sensitive and specific detection of HPA-4 and six low frequency β3-HPA antibodies
Incidence of diagnosis of subsegmental pulmonary emboli using multidetector row and single-detector row computed tomography
Testing aspirin resistance using the platelet function analyzer-100: some methodological caveats and considerations
Type 2M von Willebrand disease: a variant of type 2A?
Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies
The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1
An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1
Size isn't everything
Invitation to a debate on the serological criteria that define the antiphospholipid syndrome
Join ISTH
ANNOUNCEMENTS